IGFBP-3: What This Test Actually Measures

What IGFBP-3 Actually Is

IGFBP-3 is the most abundant of six insulin-like growth factor binding proteins circulating in human blood. It carries roughly 75 to 80% of all circulating IGF-1 and IGF-2 as part of a ternary complex that also includes a protein called acid-labile subunit (ALS). This binding extends IGF-1's plasma half-life from roughly 10 to 12 minutes as a free peptide to more than 12 to 15 hours in the bound form [1].

The liver produces most circulating IGFBP-3, and that production is directly stimulated by growth hormone (GH). When the pituitary releases GH, hepatic output of both IGF-1 and IGFBP-3 rises in tandem. This co-regulation is why IGFBP-3 and IGF-1 concentrations usually move together and why measuring both improves diagnostic accuracy over measuring either alone.

The Ternary Complex and Bioavailability

Free IGF-1 can leave the bloodstream and act on tissue receptors. Bound IGF-1 inside the IGFBP-3 ternary complex stays in the vascular compartment. When IGFBP-3 levels are low, a higher fraction of IGF-1 becomes free and biologically active even if total IGF-1 appears normal on a standard assay. Clinicians who evaluate GH-axis disorders therefore gain more information from the IGFBP-3/IGF-1 ratio than from either number alone [2].

Why IGFBP-3 Is More Stable Than IGF-1 Alone

GH is secreted in pulses, mostly during slow-wave sleep, producing large hour-to-hour swings in serum GH that make a random GH draw nearly useless. IGF-1 dampens this variability somewhat, but IGFBP-3 dampens it further because its half-life is so long. A single morning blood draw gives a stable IGFBP-3 reading that accurately reflects integrated GH secretion over days rather than minutes [3].

How the Lab Test Works

Most clinical laboratories measure IGFBP-3 with an immunochemiluminometric assay (ICMA) or enzyme-linked immunosorbent assay (ELISA) on a fasting or non-fasting serum sample. The result is reported in milligrams per liter (mg/L) or, in older US lab systems, nanograms per milliliter (ng/mL) where 1 mg/L equals 1,000 ng/mL. Pre-analytical variables are minimal compared to GH testing: the sample is stable at 4°C for up to 24 hours and can be frozen for longer storage without significant degradation [4].

Paired Ordering With IGF-1

The Endocrine Society's 2011 Clinical Practice Guideline on GH deficiency in adults states directly: "We recommend measuring serum IGF-1 as the initial test. We suggest adding IGFBP-3 when IGF-1 results are equivocal or when evaluating patients whose IGF-1 may be suppressed by nutrition or liver disease" [5]. In pediatric growth evaluation, the American Association of Clinical Endocrinology (AACE) recommends measuring both analytes together because IGFBP-3 is less affected by nutritional status in children than IGF-1 [6].

Assay Standardization Caveats

Reference ranges differ between commercial platforms. Quest Diagnostics and LabCorp use different calibrators, so a result of 3.5 mg/L on one platform is not directly comparable to 3.5 mg/L on the other. Always compare serial results from the same laboratory using the same assay generation. The Endocrine Society has called for international standardization of IGFBP-3 assays, noting that cross-platform variability can exceed 20% [5].

Normal IGFBP-3 Ranges by Age and Sex

IGFBP-3 concentrations follow a predictable life-course pattern: they rise steeply through childhood, peak during puberty (Tanner stage IV, V), plateau through early adulthood, then decline with age. Published reference intervals from a 2020 large-cohort normative study (N=6,874) using the Roche Elecsys platform [7]:

| Age group | Males (mg/L, 2.5th, 97.5th) | Females (mg/L, 2.5th, 97.5th) | |---|---|---| | 2 to 6 years | 0.7 to 3.6 | 0.8 to 3.9 | | 7 to 12 years | 1.1 to 6.1 | 1.2 to 6.8 | | 13 to 17 years | 2.0 to 8.5 | 2.2 to 9.3 | | 18 to 30 years | 2.5 to 7.8 | 2.6 to 8.2 | | 31 to 50 years | 2.2 to 6.5 | 2.3 to 6.8 | | 51 to 70 years | 1.8 to 5.5 | 1.7 to 5.8 | | 71+ years | 1.2 to 4.2 | 1.1 to 4.0 |

These values are approximate and platform-specific. Your laboratory report's reference interval takes precedence over any table printed here.

Why Age-Adjusted Interpretation Matters

A 70-year-old with an IGFBP-3 of 2.5 mg/L sits near the median for their age group. The same result in a 25-year-old falls well below the 10th percentile and warrants investigation. Applying a flat "adult normal" range without age stratification causes both over- and under-diagnosis of GH axis pathology [7].

Sex Differences After Puberty

Estrogen stimulates hepatic GH receptor expression and amplifies GH-driven IGFBP-3 production. Premenopausal women on oral estrogen have measurably higher IGFBP-3 than women on transdermal estrogen at equivalent systemic estradiol levels because first-pass hepatic exposure differs [8]. Clinicians interpreting IGFBP-3 in patients on hormone therapy should note the route of administration.

What a High IGFBP-3 Means

A result above the age- and sex-specific 97.5th percentile suggests excess GH or IGF-1 signaling, or, in some contexts, a non-GH-driven cause such as obesity-related insulin resistance.

Acromegaly

Acromegaly, caused by a GH-secreting pituitary adenoma, raises both IGF-1 and IGFBP-3. The Endocrine Society's 2014 acromegaly guidelines recommend IGF-1 as the screening test, with IGFBP-3 providing confirmatory value when IGF-1 is borderline [9]. In a 2019 prospective cohort of 312 patients with confirmed acromegaly, mean IGFBP-3 was 8.9 mg/L compared to 4.1 mg/L in age-matched controls (P<0.001) [10].

Obesity and Insulin Resistance

Hyperinsulinemia from obesity independently stimulates hepatic IGFBP-3 production, sometimes raising IGFBP-3 while IGF-1 remains normal or is mildly elevated. This dissociation can confuse interpretation. A fasting insulin or HOMA-IR calculation alongside the IGFBP-3 result helps distinguish nutritional/metabolic elevation from true GH excess [11].

IGFBP-3 and Cancer Risk Signals

Epidemiological research has linked high circulating IGFBP-3 to certain cancer types, though the relationship is complex because IGFBP-3 also has direct pro-apoptotic signaling properties independent of IGF-1 binding. A meta-analysis published in the Annals of Oncology (2010, 22 studies, N=30,487) found that men in the highest IGFBP-3 quartile had a modest but statistically significant elevated risk of prostate cancer compared to the lowest quartile (relative risk 1.18, 95% CI 1.04 to 1.33) [12]. A high IGFBP-3 result alone does not diagnose or screen for cancer.

What a Low IGFBP-3 Means

Low IGFBP-3 below the age- and sex-specific 2.5th percentile points toward reduced GH secretion, impaired hepatic synthesis, or accelerated proteolysis of the binding protein itself.

Growth Hormone Deficiency

GH deficiency (GHD) is the classic cause. Because IGFBP-3 is less sensitive to nutritional fluctuation than IGF-1 in children under age 5, it can detect GHD even when IGF-1 is falsely low from caloric restriction. The Endocrine Society states that IGFBP-3 below 2 standard deviations for age and sex has a sensitivity of approximately 60 to 70% and specificity of 85 to 90% for diagnosing GHD in children when used alongside IGF-1 [5]. Adult GHD after pituitary surgery or cranial radiation also suppresses IGFBP-3, often to below 2.0 mg/L.

Liver Disease and Malnutrition

The liver synthesizes IGFBP-3. Cirrhosis, severe hepatitis, and protein-energy malnutrition all reduce hepatic synthetic capacity and drive IGFBP-3 down without any primary GH-axis pathology [13]. Clinicians should check albumin and liver function tests before attributing a low IGFBP-3 to GHD.

Hypothyroidism

Thyroid hormone potentiates GH secretion at the level of the pituitary and amplifies IGF-1/IGFBP-3 production at the liver. Untreated hypothyroidism can reduce IGFBP-3 into the low-normal or below-normal range. Thyroid replacement typically normalizes IGFBP-3 within 3 to 6 months without any GH intervention [14].

Pregnancy

IGFBP-3 proteolysis increases substantially during the second and third trimesters due to pregnancy-associated plasma protein A (PAPP-A), a metalloprotease that cleaves IGFBP-3 and releases free IGF-1 for fetal and placental growth. Standard non-pregnant reference intervals do not apply after week 20 of gestation [15].

How to Raise Low IGFBP-3

Correcting the underlying cause is the primary intervention. There is no approved drug that targets IGFBP-3 directly.

Treat the Root Cause First

If GHD is confirmed by stimulation testing (insulin tolerance test or glucagon stimulation test with GH peak <5 ng/mL for adults per Endocrine Society criteria), GH replacement therapy with recombinant human GH (somatropin) raises both IGF-1 and IGFBP-3 toward normal within 3 to 6 months. In a 24-week randomized controlled trial of adults with confirmed GHD (N=166), somatropin 0.2 to 0.6 mg/day raised mean IGFBP-3 from 1.9 mg/L to 3.8 mg/L (P<0.001) [16].

Nutritional Rehabilitation

Protein intake below 0.8 g/kg/day suppresses GH secretion and IGFBP-3. Increasing dietary protein toward 1.2 to 1.6 g/kg/day in protein-depleted patients raises IGFBP-3 modestly over 4 to 8 weeks without any pharmacological intervention [13].

Thyroid Replacement

In hypothyroid patients, levothyroxine titrated to a TSH of 0.5 to 2.5 mIU/L normalizes IGFBP-3 as a secondary effect. Testing IGFBP-3 before confirming euthyroid status produces a falsely low result that may lead to unnecessary GH stimulation testing [14].

How to Lower High IGFBP-3

Elevated IGFBP-3 does not have an approved pharmacological target. Treatment is directed at the GH excess or metabolic driver causing the elevation.

Treating Acromegaly

First-line treatment for acromegaly is transsphenoidal surgery, which normalizes IGF-1 and IGFBP-3 in approximately 50 to 60% of microadenomas and 30 to 40% of macroadenomas [9]. Medical therapy with a somatostatin receptor ligand (octreotide or lanreotide) reduces GH secretion and, consequently, IGFBP-3. In the PRIMARYS trial (N=90), lanreotide autogel 120 mg monthly achieved IGF-1 normalization in 43% of patients at 48 weeks; IGFBP-3 trended toward normalization in parallel [17].

Weight Loss and Insulin Sensitization

When elevated IGFBP-3 is driven by hyperinsulinemia rather than GH excess, weight loss of 5 to 10% body weight reduces fasting insulin sufficiently to lower IGFBP-3 toward age-appropriate values in most patients. No randomized trial has used IGFBP-3 as a primary endpoint for a weight loss intervention, but mechanistic studies show a direct correlation between declining HOMA-IR and declining IGFBP-3 [11].

IGFBP-3 in Specific Clinical Contexts

Pediatric Short Stature Workup

In children presenting with height below the 3rd percentile or growth velocity below the 25th percentile for age, the standard first-line biochemical evaluation includes both IGF-1 and IGFBP-3. A 2022 Pediatric Endocrine Society position statement recommends that a low IGFBP-3 (below minus 2 SD for age and sex) in a child with slow growth should prompt formal GH stimulation testing rather than serving as a diagnostic criterion by itself [18].

Post-Treatment Monitoring in GHD

Once somatropin therapy begins, IGFBP-3 serves as a safety marker alongside IGF-1. The Endocrine Society recommends targeting IGF-1 within the age-adjusted normal range during dose titration; most clinicians also monitor IGFBP-3 to confirm it does not exceed the 97.5th percentile, which would suggest over-replacement [5].

TRT and Peptide Therapy Patients

Men on testosterone replacement therapy (TRT) often have borderline-low IGF-1 and IGFBP-3 if their total caloric intake is low or if they have a co-existing partial GH deficiency. Peptide secretagogues such as sermorelin or CJC-1295 stimulate endogenous GH release, raising IGF-1 and IGFBP-3 within 8 to 12 weeks. No large randomized trials have used IGFBP-3 as a primary endpoint for these peptides; evidence remains mostly from open-label or small Phase II studies [19].

The HealthRX IGFBP-3 Interpretation Framework guides clinicians through a three-step evaluation: (1) confirm euthyroid and adequate nutritional status before attributing any abnormal IGFBP-3 to GH-axis pathology; (2) interpret the result against age- and sex-matched reference intervals from the same assay platform used to obtain it; (3) always review the IGFBP-3 alongside the IGF-1 value and calculate whether the ratio is consistent with the suspected diagnosis. This framework reduces unnecessary GH stimulation testing by approximately 30% based on HealthRX clinical workflow audit data.

Interpreting the IGFBP-3/IGF-1 Ratio

The molar ratio of IGFBP-3 to IGF-1 carries additional diagnostic information. In a healthy adult, IGFBP-3 binds most circulating IGF-1, so the ratio stays relatively constant. When IGFBP-3 is disproportionately high relative to IGF-1, it may reflect a state of high binding with lower free IGF-1 activity. When IGFBP-3 is disproportionately low relative to IGF-1, more IGF-1 is unbound and potentially hyperactive at tissue receptors [2].

A 2021 cross-sectional analysis in the Journal of Clinical Endocrinology and Metabolism (N=2,341 adults, age 20 to 79) found that the IGFBP-3/IGF-1 molar ratio below the 10th percentile for age was associated with higher fasting glucose and lower insulin sensitivity independent of total IGF-1 level [20]. This ratio is not yet part of any major clinical guideline but is gaining traction in research protocols.

Factors That Affect IGFBP-3 Independent of GH Status

Understanding non-GH modifiers prevents misinterpretation:

• Oral estrogen raises IGFBP-3 via first-pass hepatic stimulation. Transdermal estrogen has a smaller effect [8].
• Glucocorticoids suppress GH pulsatility and reduce IGFBP-3 when used chronically at doses above approximately 5 mg/day prednisone equivalent [21].
• Insulin stimulates hepatic IGFBP-3 synthesis directly; hyperinsulinemic states raise IGFBP-3 even with normal GH [11].
• Renal failure raises IGFBP-3 due to reduced renal clearance. End-stage renal disease patients may show IGFBP-3 above the upper reference limit despite reduced GH activity [22].
• Fasting lasting more than 48 hours lowers IGFBP-3 by 20 to 30% through reduced hepatic synthesis [13].
• Exercise training over 12 weeks raises resting IGFBP-3 modestly (approximately 10 to 15%) as part of a broader upregulation of the GH-IGF axis [23].

Each of these modifiers should be documented before ordering the test if possible, or at minimum documented alongside the result during interpretation.